Enrolling By InvitationNCT07356765
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
This study evaluates the effectiveness of Berberine for people with schizophrenia.
Medication studyAges 18–60China
Understand this study
What is this study about?
This study evaluates the effectiveness of Berberine for people with schizophrenia.
Who could participate?
Listed age limits: 18 years to 60 years.
- Listed locations
- TianjinSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 26, 2023
- Recruitment status
- Enrolling By Invitation
- Enrollment listed in the registry
- 120
- Sponsor
- Tianjin Anding Hospital
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- China
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT07356765
- Official title
Show the full official title
Berberine in Treating Negative Symptoms of Schizophrenia: Clinical Efficacy and Mechanisms
Recruitment & locations
By invitationThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tianjin
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the effectiveness of Berberine for people with schizophrenia.
Who is behind this study?
The study sponsor is Tianjin Anding Hospital, a hospital or academic medical center.
Does this study involve medication?
Yes. The study involves medication, including Berberine.
Who can participate?
Listed age limits: 18 years to 60 years.
Is this study still recruiting?
The registry lists this study as enrolling by invitation.
Want to explore more studies?
Explore studiesRelated studies
A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia
tACS to Improve Negative Symptoms & Cognition in Long-term Hospitalized Schizophrenia Patients.
